Soleno Therapeutics Company Profile Get Rating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Soleno therapeutics company profile get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Soleno Therapeutics Company Profile Get Rating Today - Breaking & Trending Today

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Expected to Announce Earnings of -$0.07 Per Share

Analysts expect that Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Rating) will announce ($0.07) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics posted earnings per share of ($0.14) in the same quarter last year, which indicates a positive year-over-year […] ....

Soleno Therapeutics Inc , Geode Capital Management , Soleno Therapeutics Company Profile Get Rating , Zacks Investment Research , Blackrock Inc , Renaissance Technologies , Soleno Therapeutics , Get Rating , Zacks Investment , Soleno Therapeutic , Investment Research , Capital Management , Two Sigma Investments , Sigma Investments , Therapeutics Company Profile , Diazoxide Choline Controlled Release , Prader Willi Syndrome , Nasdaq Slno ,

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Short Interest Down 25.5% in April

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Rating) was the target of a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 283,400 shares, a decrease of 25.5% from the April 15th total of 380,300 shares. Approximately 0.4% of the company’s shares are short sold. Based […] ....

Soleno Therapeutics Inc , Geode Capital Management , Capital Management , Soleno Therapeutics Company Profile Get Rating , Zacks Investment Research , Soleno Therapeutics , Get Rating , Asset Management , Sigma Advisers , Therapeutics Company Profile , Diazoxide Choline Controlled Release , Prader Willi Syndrome , Nasdaq Slno ,

Soleno Therapeutics (NASDAQ:SLNO) Raised to Buy at Zacks Investment Research

Soleno Therapeutics (NASDAQ:SLNO – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Zacks.com reports. The firm presently has a $0.25 price target on the stock. Zacks Investment Research‘s target price suggests a potential upside of 15.21% from the stock’s […] ....

Nova Scotia , British Columbia , Soleno Therapeutics Inc , Soleno Therapeutics Company Profile Get Rating , Zacks Investment Research , Blackrock Inc , Millennium Management , Capnia Inc , Soleno Therapeutics , Get Rating , Investment Research , Serenz Nasal , Sigma Advisers , Sigma Investments , Therapeutics Company Profile , Diazoxide Choline Controlled Release , Prader Willi Syndrome , Nasdaq Slno ,

Soleno Therapeutics, Inc. (NASDAQ:SLNO) to Post FY2026 Earnings of $0.63 Per Share, Oppenheimer Forecasts

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Rating) – Investment analysts at Oppenheimer issued their FY2026 earnings per share estimates for shares of Soleno Therapeutics in a research note issued to investors on Monday, April 4th. Oppenheimer analyst L. Gershell expects that the company will earn $0.63 per share for the year. Soleno Therapeutics (NASDAQ:SLNO – […] ....

Soleno Therapeutics Inc , Soleno Therapeutics Company Profile Get Rating , Zacks Investment Research , Blackrock Inc , Millennium Management , Soleno Therapeutics , Get Rating , Sigma Advisers , Sigma Investments , Therapeutics Company Profile , Diazoxide Choline Controlled Release , Prader Willi Syndrome , Nasdaq Slno , Earnings Estimates , Oppenheimer Holdings Inc ,

Soleno Therapeutics (NASDAQ:SLNO) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Soleno Therapeutics (NASDAQ:SLNO – Get Rating) issued its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.05, MarketWatch Earnings reports. Soleno Therapeutics stock opened at $0.22 on Friday. The company has a market cap of $17.80 million, a P/E ratio […] ....

Thomson Reuter , Soleno Therapeutics Inc , Geode Capital Management , Soleno Therapeutics Company Profile Get Rating , Zacks Investment Research , Renaissance Technologies , Millennium Management , Soleno Therapeutics , Get Rating , Marketwatch Earnings , Sigma Investments , Capital Management , Therapeutics Company Profile , Diazoxide Choline Controlled Release , Prader Willi Syndrome , Nasdaq Slno ,